<p>TKI, tyrosine kinase inhibitors; CCRT, concurrent chemoradiation therapy.</p><p>Note.—Data are mean ± standard deviation of the percent change n the given parameter.</p><p>* <i>P</i> <.05.</p
<p>Plots of <b>(a)</b> the mean ADC change and <b>(b)</b> the percentage of voxels with significantl...
<p>CT2 and CT4 are 2- and 4-day control groups; and TX2 and TX4 are 2- and 4-day treatment groups. A...
<p>CT: chemotherapy, mean±standard deviation,</p><p>*<i>p</i><0.05</p><p>Comparison of the QOL-ACD t...
<p>TKI, tyrosine kinase inhibitors; CCRT, concurrent chemoradiation therapy; AUC, area under the cur...
<p>Percentage changes of vascular and metabolic parameters compared with the baseline at each time p...
Percentage change in tumour volume between the 6 month, 12 month, 24 month and last follow-up CT rel...
<div><p>Background and Purpose</p><p>To correlate changes of various CT parameters after the neoadju...
Purpose: To assess the changes in tumor CT texture following 2 cycles of TKIs; and to determine if...
In this paper, we assess changes in CT texture of metastatic liver lesions after treatment with chem...
<p>(a) Combined histogram distributions of the treatment before (blue) and after (red). As for histo...
<p>Percentage of BTM changes from baseline in the two groups of chemotherapy regimens.</p
BACKGROUND AND PURPOSE: To correlate changes of various CT parameters after the neoadjuvant treatmen...
<p>Sensitivity analysis of the influence of C vs. T in overall cancer meta–analysis (fixed–effects e...
<p>TKI, tyrosine kinase inhibitors; CCRT, concurrent chemoradiation therapy.</p><p>Note.—Unless othe...
<p>CT study protocols and patient characteristics. Scan Range/Patients data presented as means±stand...
<p>Plots of <b>(a)</b> the mean ADC change and <b>(b)</b> the percentage of voxels with significantl...
<p>CT2 and CT4 are 2- and 4-day control groups; and TX2 and TX4 are 2- and 4-day treatment groups. A...
<p>CT: chemotherapy, mean±standard deviation,</p><p>*<i>p</i><0.05</p><p>Comparison of the QOL-ACD t...
<p>TKI, tyrosine kinase inhibitors; CCRT, concurrent chemoradiation therapy; AUC, area under the cur...
<p>Percentage changes of vascular and metabolic parameters compared with the baseline at each time p...
Percentage change in tumour volume between the 6 month, 12 month, 24 month and last follow-up CT rel...
<div><p>Background and Purpose</p><p>To correlate changes of various CT parameters after the neoadju...
Purpose: To assess the changes in tumor CT texture following 2 cycles of TKIs; and to determine if...
In this paper, we assess changes in CT texture of metastatic liver lesions after treatment with chem...
<p>(a) Combined histogram distributions of the treatment before (blue) and after (red). As for histo...
<p>Percentage of BTM changes from baseline in the two groups of chemotherapy regimens.</p
BACKGROUND AND PURPOSE: To correlate changes of various CT parameters after the neoadjuvant treatmen...
<p>Sensitivity analysis of the influence of C vs. T in overall cancer meta–analysis (fixed–effects e...
<p>TKI, tyrosine kinase inhibitors; CCRT, concurrent chemoradiation therapy.</p><p>Note.—Unless othe...
<p>CT study protocols and patient characteristics. Scan Range/Patients data presented as means±stand...
<p>Plots of <b>(a)</b> the mean ADC change and <b>(b)</b> the percentage of voxels with significantl...
<p>CT2 and CT4 are 2- and 4-day control groups; and TX2 and TX4 are 2- and 4-day treatment groups. A...
<p>CT: chemotherapy, mean±standard deviation,</p><p>*<i>p</i><0.05</p><p>Comparison of the QOL-ACD t...